Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05394103 · ClinicalTrials.gov registry record · Phase 1
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
A Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by Qurient Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 11
- Study locations
NCT05394103: Recruiting Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by Qurient Co..
NCT05394103 is a Phase 1 study of Advanced Cancer and Metastatic Cancer that is actively recruiting participants, run by Qurient Co.. The registered enrollment target is 130 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05394103, a Phase 1 study of Advanced Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Qurient Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 11
- Study locations
Study Summary
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Conditions Studied
Interventions
- DRUG Q901
- DRUG KEYTRUDA® (pembrolizumab)
Study Locations (11)
Other
- National Cancer Center - Goyang-si
- CHA University Bundang Medical Center - Seongnam-si
- Asan Medical Center - Seoul
- Severance Hospital - Seoul
Arizona
- Mayo Clinic - Phoenix
California
- University of Southern California - Los Angeles
Florida
- Mayo Clinic - Jacksonville
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Atlantic Health System Hospital - Morristown
Texas
- Mary Crowley Cancer Research - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 1 |
What NCT05394103 shows while recruiting
NCT05394103 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Q901 is the first listed.
NCT05394103 lists 11 locations in 8 states (Other, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT05394103 about?
NCT05394103 is a clinical study titled "Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors". Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
What is the current status of trial NCT05394103?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2022-08-30. Estimated completion is 2026-08-30.
What conditions does trial NCT05394103 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT05394103?
The interventions under investigation include: Q901 (DRUG), KEYTRUDA® (pembrolizumab) (DRUG).
Who is sponsoring clinical trial NCT05394103?
This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05394103 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05394103's enrollment target sits among peer trials
130 52nd of 122 higher than 71 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI